EpiVax, Inc. unveils AI-enabled enhancements to ISPRI, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics.
The company has updated the JanusMatrix model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk.
New updates
ISPRI aims to better assess immunogenicity risk across candidate and impurity sequences by bringing together tools such as EpiMatrix and JanusMatrix, which evaluate T cell epitope content and human cross-conservation to characterise sequence-derived immunogenicity risk and immune tolerance.
New updates include the following:
- JanusMatrix 2.1
JanusMatrix 2.1 applies AI to improve immune-tolerance prediction by weighting human epitope cross-conservation based on expression and prevalence data, improving precision in characterising therapeutic epitopes and their tolerance profiles.
- JanusMatrix-Adjusted EpiMatrix Score
Building on JanusMatrix 2.1, EpiVax unveils a new immunogenicity score designed to align more closely with clinical immunogenicity outcomes. The JanusMatrix-Adjusted EpiMatrix (JAX) score incorporates JanusMatrix tolerance potential directly into EpiMatrix scores to provide insight into intrinsic effector epitope density and a more biologically informed assessment of sequence-derived immunogenicity risk across therapeutic modalities.
- ADA 2.2
The ADA 2.2 model now combines epitope-based measures with biophysical attributes, providing a more reliable assessment of antibody immunogenicity risk
